Ixabepilone, Free Base (Azaepothilone B, BMS-247550, BMS 247550-1, Ixempra, CAS 219989-84-1), >99%

LC Laboratories' Product Number I-5022 - Ixabepilone, Free Base (Azaepothilone B, BMS-247550, BMS 247550-1, Ixempra, CAS 219989-84-1), >99% - for research use only. Ixabepilone, also known as BMS-247550, is an epothilone B analog and microtubule-stabilizing agent. Ixabepilone showed potent induction of tubulin polymerization, with an EC0.01 value of 3.5 µM (about 2-fold lower than paclitaxel, please see Cat. No. P-9600, Paclitaxel). Ixabepilone showed activity against 21 paclitaxel-sensitive and paclitaxel-resistant cell lines with IC50 values of 1.4 - 34.5 nM and retained its antineoplastic activity against human cancers that were naturally insensitive to paclitaxel or that had developed resistance to paclitaxel in vivo. Ixabepilone demonstrated superior preclinical characteristics, including high metabolic stability, low plasma protein binding (79.4%) and low susceptibility to multidrug resistance protein-mediated efflux. Combined treatment with ixabepilone and capecitabine (please see Cat. No. C-2799, Capecitabine) in an international phase 3 study demonstrated superior efficacy to capecitabine alone in patients with metastatic breast cancer pretreated with or resistant to anthracyclines and resistant to taxanes. Ixabepilone is the active ingredient in the drug product sold under the trade name Ixempra®. This drug is currently approved in at least one country for use in patients with aggressive metastatic or locally advanced breast cancer no longer responding to currently available chemotherapies. NOTE: THE IXABEPILONE FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT IXEMPRA®, AND IS NOT FOR HUMAN USE.

• Supplier: LC Laboratories
• Product #: I-5022
• Sku #: I-5022_1mg